|
Combination immunotherapy selection for PD-1 axis driven tumors. |
| |
|
|
Stock and Other Ownership Interests - OmniSeq |
Patents, Royalties, Other Intellectual Property - OmniSeq (Inst) |
| |
|
|
Stock and Other Ownership Interests - OmniSeq |
| |
|
|
Stock and Other Ownership Interests - OmniSeq |
| |
|
|
Stock and Other Ownership Interests - OmniSeq |
Patents, Royalties, Other Intellectual Property - OmniSeq (Inst) |
| |
|
|
Stock and Other Ownership Interests - OmniSeq |
Patents, Royalties, Other Intellectual Property - OmniSeq (Inst) |
| |
|
|
Stock and Other Ownership Interests - OmniSeq |
Patents, Royalties, Other Intellectual Property - OmniSeq (Inst) |
| |
|
|
Stock and Other Ownership Interests - OmniSeq |
| |
|
|
Stock and Other Ownership Interests - OmniSeq |
| |
|
|
Stock and Other Ownership Interests - OmniSeq |
| |
|
|
Stock and Other Ownership Interests - OmniSeq |
| |
|
No Relationships to Disclose |
| |
Antonios Papanicolau-Sengos |
No Relationships to Disclose |
| |
|
Employment - Boehringer Ingelheim (I); OmniSeq |
| |
|
No Relationships to Disclose |
| |
|
|
|
Stock and Other Ownership Interests - OmniSeq |
Consulting or Advisory Role - NanoString Technologies |
Patents, Royalties, Other Intellectual Property - OmniSeq (Inst) |